课题基金 / 基金详情

Investigating the role of LAG3 in regulatory and effector T cells in systemic lupus erythematosus

Investigating the role of LAG3 in regulatory and effector T cells in systemic lupus erythematosus
研究 LAG3 在系统性红斑狼疮调节性 T 细胞和效应 T 细胞中的作用
批准号:
MR/V033573/1
负责人:
Michael Ehrenstein
金额:
$15.51万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2021
资助国家:
英国
项目状态:
已结题
起止时间:
2021 至 --

项目摘要

项目成果

Michael Ehrenstein的其他基金

相似基金

相关文献

中文摘要
翻译
葛兰素史克已经开发出一种用于治疗的单抗,可以将激活的免疫细胞(称为T细胞)从体内移除,而T细胞在许多自身免疫性疾病中是重要的。这些被激活的T细胞可以引起炎症,其表面有一种名为LAG3的分子。据报道,LAG3也由另一种T细胞表达,这种T细胞可以抑制炎症,称为调节性T细胞。事实上,LAG3在T细胞上的作用还不是很清楚。这项建议的目的是为关于这种抗体是否可以用于治疗系统性红斑狼疮(SLE)患者的决定提供信息。系统性红斑狼疮是一种自身免疫性疾病,主要影响育龄妇女,可导致严重疾病甚至过早死亡。对于这种情况,可用的治疗方法很少,患者经常不得不依赖类固醇的使用,这会产生严重而显著的副作用。已知激活的和调节的T细胞在SLE中都是异常的,可能导致疾病。我们将测定LAG3在血液和尿液中活化和调节T细胞上的分布,后者反映了SLE患者肾脏中经常受到影响的T细胞。我们这样做是因为重要的是,我们不能通过使用这种抗体来治疗患者而导致更多的炎症,如果表面有LAG3的细胞中有相当大一部分试图抑制而不是引起炎症,就可能发生这种情况。接下来,我们将把正在耗尽的抗LAG3抗体添加到SLE患者的血液细胞中,看看总体效果是减轻还是增加炎症。我们将测量T细胞的激活状态,无论是激活的还是调节性的T细胞从培养中移除,以及这如何影响引起细胞因子的炎症的产生。我们将评估这些实验的结果,以决定是否使用这种抗LAG3抗体进行临床试验,如果这项建议的结果令人鼓舞,这将是下一步,即抗LAG3去除了引起炎症的T细胞,但不是免疫抑制调节性T细胞。这项临床试验将与其他著名中心合作,并将在该项目完成后考虑资助。
英文摘要
GSK have developed a monoclonal antibody for therapy that removes activated immune cells (called T cells), which are important in many autoimmune diseases, from the body. These activated T cells, which can cause inflammation, have a molecule on their surface called LAG3. LAG3 has also been reported to be expressed by another T cell which can suppress inflammation called regulatory T cells. In fact, the role of LAG3 on T cells is not well understood. The aim of this proposal is to inform a decision as to whether this antibody could be used to treat patients with systemic lupus erythematosus (SLE). SLE is an autoimmune disease, predominantly affecting women of child-bearing age, which can cause serious disease and even early death. There are few treatments available for this condition, and patients often have to rely on the use of steroids, which have serious and significant side effects. Both activated and regulatory T cells are known to be abnormal in SLE and could contribute to disease. We will determine the distribution of LAG3 on activated and regulatory T cells in the blood and urine, the latter reflects the T cells in the kidney often affected in SLE, in patients with SLE. We are doing this because it is important we do not cause more inflammation by using this antibody to treat patients, which might happen if a significant proportion of those cells that have LAG3 on their surface are trying to suppress, rather than cause, inflammation.We will next add the depleting anti-LAG3 antibody to cells taken from the blood of patients with SLE to see whether the overall effect is to reduce or increase inflammation. We will measure the activation status of the T cells, whether activated or regulatory T cells are removed from the cultures, and how this affects the production of inflammation causing cytokines. We will assess the results of these experiments to decide whether to proceed to a clinical trial using this anti-LAG3 antibody, which will be the next step if the results from this proposal are encouraging i.e. anti-LAG3 removes T cells causing inflammation but not immune suppressing regulatory T cells. This clinical trial will be in collaboration with other EMINENT centres and will be considered for funding after this project has completed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel combination therapy for rheumatoid arthritis: efficacy of anti-CD3 antibody enhanced by p38 inhibitor (Work packages 1-4)
  • 批准号:
    MR/P50208X/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $19.24万
  • 财政年份:
    2017
  • 负责人:
    Michael Ehrenstein
  • 依托单位:
国内基金
海外基金
水稻根长与抗旱基因RoLe1的克隆与分子机制解析
  • 批准号:
    32401809
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2024
  • 负责人:
    李颖秀
  • 依托单位:
PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
Sestrin2抑制内质网应激对早产儿视网膜病变的调控作用及其机制研究
  • 批准号:
    82371070
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    赵培泉
  • 依托单位: